Derisking Orphan Drug Programs in 2020 and Beyond
Summary: Dramatically shifting the attention of the industry, Covid-19 forced orphan developers to re-examine their go-to-market strategies.
Developing Optimal Formulations Using Biorelevant Predictive Tools and Advanced Bioavailability Enhancement Technologies
Summary: Low bioavailability can lead to development challenges. Advanced formulation expertise and technologies can increase the chance of success in the clinic.
Interview: Fierce Pharma with Jeremie Trochu
Summary: Jeremy Trochu, Vice President and General Manager of Pharmaceutical Development Services at Catalent, recently sat down for an interview…
Next-Generation Orphan Drug Delivery
Summary: Big Pharma used to ignore this segment of the market, but now developing orphan drugs to treat these rare diseases is an industry priority.
The Future of Orphan Drugs: Insights on the Current Market, Trends & Strategic Partnerships Driving Innovation
Summary: In this report, we will highlight the trends shaping the orphan-drug market, with a particular focus on expedited drug development. Expert insights on navigating development and manufacturing challenges with…
Early Phase Solutions
Summary: Explore how you can leverage Catalent’s successful track record optimizing thousands of molecules, deep development expertise and broadest set of superior technologies to…